Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

References

• Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Rev Clin Oncol. 2016;13(11):674-90. doi:10.1038/nrclinonc.2016.66. PMID:27184417
   PubMed Web of Science ®Google Scholar
• Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533-40. doi:10.1158/1078-0432.CCR-13-0799. PMID:23948975
   PubMed Web of Science ®Google Scholar
• Arpino G, Generali D, Sapino A, Del Mastro L, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, et al. Gene expression profiling in breast cancer: a clinical perspective. Breast. 2013;22(2):109-20. doi:10.1016/j.breast.2013.01.016. PMID:23462680
   PubMed Web of Science ®Google Scholar
• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008. doi:10.1101/cshperspect.a001008. PMID:20182602
   PubMed Web of Science ®Google Scholar
• Bueter M, Gasser M, Lebedeva T, Benichou G, Waaga-Gasser AM. Influence of p53 on anti-tumor immunity (review). Int J Oncol. 2006;28(2):519-25. PMID:16391808
   PubMed Web of Science ®Google Scholar
• Song GY, Gibson G, Haq W, Huang EC, Srivasta T, Hollstein M, Daftarian P, Wang Z, Diamond D, Ellenhorn JD. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother. 2007;56(8):1193-205. doi:10.1007/s00262-006-0270-3. PMID:17219151
   PubMed Web of Science ®Google Scholar
• Song GY, Srivastava T, Ishizaki H, Lacey SF, Diamond DJ, Ellenhorn JD. Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion. Cancer Invest. 2011;29(8):501-10. doi:10.3109/07357907.2011.606248. PMID:21843052
   PubMed Web of Science ®Google Scholar
• Liu X, Peralta EA, Ellenhorn JD, Diamond DJ. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Cancer Res. 2000;60(3);693-701. PMID: 10676655
   PubMed Web of Science ®Google Scholar
• Hardwick NR, Carroll M, Kaltcheva T, Qian D, Lim D, Leong L, Chu P, Kim J, Chao J, Fakih M, et al. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clin Cancer Res. 2014;20(17):4459-70. doi:10.1158/1078-0432.CCR-13-3361. PMID:24987057
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361-70. doi:10.1158/2326-6066.CIR-13-0127. PMID:24764583
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraia K, Aktan G, Cheng JD, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460-7. doi:10.1200/JCO.2015.64.8931. PMID:27138582
   PubMed Web of Science ®Google Scholar
• Hartkopf AD, Taran FA, Wallwiener M, Walter CB, Kramer B, Grischke EM, Brucker SY. PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer. Breast Care. 2016;11(6):385-90. doi:10.1159/000453569. PMID:28228704
   PubMed Web of Science ®Google Scholar
• Hardwick N, Chung V, Cristea M, Ellenhorn JD, Diamond DJ. Overcoming immunosuppression to enhance a p53MVA vaccine. Oncoimmunology. 2014;3(10):e958949. doi:10.4161/21624011.2014.958949. PMID:25941580
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275-87. doi:10.1038/nrc.2016.36. PMID:27079802
   PubMed Web of Science ®Google Scholar
• Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395-9. doi:10.1038/nature10933. PMID:22495314
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature. 2012;490(7418):61-70. doi:10.1038/nature11412. PMID:23000897
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268-86. doi:10.1101/gad.190678.112. PMID:22713868
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355(6332):1423-7. doi:10.1126/science.aaf0683. PMID:28280249
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428-33. doi:10.1126/science.aaf1292. PMID:28280247
   PubMed Web of Science ®Google Scholar
• Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2024;70(1):46-58. doi:10.1016/j.ymeth.2014.08.016. PMID:25242720
   PubMed Web of Science ®Google Scholar